Laura Rodriguez de la Fuente
Overview
Explore the profile of Laura Rodriguez de la Fuente including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
150
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Colino-Sanguino Y, Rodriguez de la Fuente L, Gloss B, Law A, Handler K, Pajic M, et al.
Heliyon
. 2024 Sep;
10(17):e37185.
PMID: 39296129
Single-cell transcriptomics has emerged as the preferred tool to define cell identity through the analysis of gene expression signatures. However, there are limited studies that have comprehensively compared the performance...
2.
Radfar P, Ding L, Rodriguez de la Fuente L, Aboulkheyr H, Gallego-Ortega D, Warkiani M
Biosens Bioelectron
. 2022 Dec;
223:114966.
PMID: 36580816
Effective isolation and in-depth analysis of Circulating Tumour Cells (CTCs) are greatly needed in diagnosis, prognosis and monitoring of the therapeutic response of cancer patients but have not been completely...
3.
McNamee N, Rodriguez de la Fuente L, Santos-Martinez M, ODriscoll L
BMC Cancer
. 2022 Sep;
22(1):1023.
PMID: 36171564
Background: Cancer patients have an increased risk of developing venous thromboembolism, with up to 30% dying within a month of their development. Some cancer cells are known to induce platelet...
4.
Rodriguez de la Fuente L, Cancela I, Estevez-Salguero A, Iglesias P, Costoya J
Anal Chim Acta
. 2022 Aug;
1221:340084.
PMID: 35934341
The development of new diagnostic tools in tumor pathology allows the optimization of individualized therapies in cancer patients. The functional optical image provides a unique opportunity to identify the pathophysiological...
5.
Law A, Chen J, Colino-Sanguino Y, Rodriguez de la Fuente L, Fang G, Grimes S, et al.
Adv Sci (Weinh)
. 2022 May;
9(21):e2103332.
PMID: 35611998
To fully investigate cellular responses to stimuli and perturbations within tissues, it is essential to replicate the complex molecular interactions within the local microenvironment of cellular niches. Here, the authors...
6.
Law A, Rodriguez de la Fuente L, Grundy T, Fang G, Valdes-Mora F, Gallego-Ortega D
Front Oncol
. 2021 Dec;
11:782766.
PMID: 34917509
Over 90% of potential anti-cancer drug candidates results in translational failures in clinical trials. The main reason for this failure can be attributed to the non-accurate pre-clinical models that are...
7.
Rodriguez de la Fuente L, Law A, Gallego-Ortega D, Valdes-Mora F
STAR Protoc
. 2021 Sep;
2(4):100841.
PMID: 34585168
Cell preparation with a high rate of viable cells is required to obtain reliable single-cell transcriptomic and epigenomic data. This protocol describes a technique for digestion and single-cell isolation from...
8.
Fang G, Lu H, Rodriguez de la Fuente L, Law A, Lin G, Jin D, et al.
Adv Sci (Weinh)
. 2021 Sep;
8(21):e2102418.
PMID: 34494727
Mammary tumor organoids have become a promising in vitro model for drug screening and personalized medicine. However, the dependency on the basement membrane extract (BME) as the growth matrices limits...
9.
Valdes-Mora F, Salomon R, Gloss B, Law A, Venhuizen J, Castillo L, et al.
Cell Rep
. 2021 Apr;
35(2):108945.
PMID: 33852842
Basal breast cancer is associated with younger age, early relapse, and a high mortality rate. Here, we use unbiased droplet-based single-cell RNA sequencing (RNA-seq) to elucidate the cellular basis of...
10.
Golan I, Rodriguez de la Fuente L, Costoya J
Cancers (Basel)
. 2018 Dec;
10(12).
PMID: 30567306
Glioblastoma (GB) is the most aggressive and most common malignant primary brain tumor diagnosed in adults. GB shows a poor prognosis and, unfortunately, current therapies are unable to improve its...